Haleon plc 6-K, filed Oct 31, 2024
Haleon plc (HLN)
6-K
2024-10-31
For: 2024-10-31
View Original
Added on
July 04, 2026
About this 6-K
Haleon plc filed this 6-K on October 31, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
31 October 2024 – “Haleon 2024 Q3 Trading
Statement”
|
|
31 October 2024 – “Haleon 2024 Q3
Trading Statement”
|
99.1
Haleon plc: 2024 Q3 Trading Statement
31 October 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its
Q3 trading update for the year ending 31 December 2024 is available
at:
http://www.rns-pdf.londonstockexchange.com/rns/3035K_1-2024-10-30.pdf
The Q3 trading update will also be available on the Haleon
website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Tobias
Hestler, Chief Financial Officer at 9:00am GMT (10:00am CET) on 31
October 2024, which can be accessed at www.haleon.com/investors/.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 800 358 1035
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 20 3936 2999
|
|
Passcode:
|
401552
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed
at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Rakesh
Patel
|
+44
7552 484646
|
Zoë Bird
|
+44
7736 746167
|
|
Emma
White
|
+44
7823 523562
|
Gemma
Thomas
|
+44 7985 175048
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
October 31, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|